Torrent Pharmaceuticals Ltd.
TORNTPHARM · NSE · Healthcare
With a 20% margin of safety, our buy-below price is ₹1,791.15.
Piotroski F-score 3/9 — quality of earnings & balance sheet.
Investability checklist
- ✓ROE above 15%17.0%
- ✕Low debt (D/E < 0.5)0.85x
- ✓Positive free cash flow
- ✓Revenue growth > 10%42%
- ✕Earnings growing-22%
- ✓Net margin ≥ 10%15.5%
- ✕Current ratio > 1.51.13
- ✕Below our fair value
- ✕Margin of safety ≥ 20%
- ✓Above 200-day average
- ✓Above 50-day average
- –Positive 1-year return
- ✓Altman Z in safe zoneZ 3.89
- ✕Piotroski ≥ 73/9
1-year price
EOD · 2026-06-15Our scores
Key fundamentals
SWOT snapshot
Strengths
- •Healthy profit margin (15.5%).
- •Trading near its 52-week high.
- •Financially solid — Altman Z 3.89.
Weaknesses
- •Weak Piotroski score (3/9).
Opportunities
- •Revenue growing (42% YoY).
Threats
- •Earnings contracting year on year.
- •Rich valuation versus sector peers.
- •Trades ~50% above our estimated fair value.
About Torrent Pharmaceuticals Ltd.
Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, marketing, and distribution of branded and generic pharmaceutical formulations in India, the United States, Brazil, Germany, Malta, and internationally. The company offers products in various therapeutic areas, including anti-diabetic, anti-microbial, cardiovascular, CNS, urology, gynecology, oncology, gastro-intestinal, nephrology, neuro-psychiatric, dermatology, pulmonology, pediatric treat
More in Healthcare
Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.